Table 2 Primary and secondary end points after 6 months (intent to treat analysis)

VO_2max, ml/kg/min

26.2 (6.0) [74]

28.1 (6.7) [61]

1.82* (2.71) [61]

28.1 (6.3) [71]

29.3 (7.1) [58]

0.66 (3.50) [58]

1.24^# (0.23 to 2.25)

< 0.001

0.25

0.056

VO_2max, ml/min

2045 (454) [74]

2197 (528) [61]

126* (239) [61]

2065 (501) [71]

2149 (556) [58]

55 (276) [58]

76 (− 7 to 158)

< 0.001

0.81

0.17

Peak power output, watt

132 (33.3) [74]

145 (38.9) [61]

10.2* (16.2) [61]

135 (34.1) [71]

145 (36.6) [58]

6.3 (18.7) [58]

3.8 (− 1.9 to 9.5)

< 0.001

0.66

0.28

Rate pressure product^d

26468 (5539) [73]

25258 (5677) [61]

− 1109* (3164) [61]

26715 (5099) [71]

26382 (4641) [58]

94.2 (3249) [58]

− 1079^# (− 2157 to − 1)

0.16

0,56

0.04

Cardiac output max, l/min

16.7 (3.3) [61]

17.7 (3.4) [55]

0.59 (2.5) [46]

17.7 (2.8) [59]

17.9 (3.5) [51]

0.17 (2.7) [43]

0.52 (− 0.4 to 1.5)

0.28

0.25

0.40

CRP, mg/l

3.2 (7.6) [76]

1.7 (1.8) [62]

− 0.7 (4.3) [62]

3.4 (14.5) [71]

1.6 (1.6) [59]

− 2.1 (16.0) [59]

0.4 (− 3.4 to 4.2)

0.22

0.85

0.66

Body cell mass, kg

30.1 (5.8) [74]

31.4 (6.6) [63]

1.0* (2.2) [63]

29.9 (6.2) [69]

30.5 (6.7) [58]

0.7* (1.7) [58]

0.3 (− 0.3 to 0.9)

< 0.001

0.75

0.59

BMI, kg/m²

26.6 (4.7) [74]

26.9 (4.5) [63]

− 0.1 (1.1) [63]

25.3 (4.4) [71]

25.1 (4.1) [60]

0.2 (0.9) [60]

− 0.3 (− 0.6 to 0.03)

0.81

0.11

0.16

EORTC QLQ-C30; global score

62.4 (21.6) [68]

67.4 (25.4) [54]

4.6 (33.4) [49]

60.1 (22.9) [65]

69.3 (18.8) [54]

13.1* (31.5) [50]

 − 4.5 (− 15 to 6.3)

0.01

0.86

0.61

Activity per week^e (> 3 MET), min

145 (160) [74]

124 (141) [68]

− 31 (129) [67]

170 (152) [69]

114 (111) [60]

− 48* (116) [58]

24.4 (− 14 to 63)

< 0.001

0.55

0.44

App use per week^e numbers

26.2 (7.7) [75]

20.8 (9.4) [70]

− 5.9* (9.2) [69]

21.2 (6.6) [71]

16.6 (7.1) [62]

− 5.0* (7.0) [62]

 − 0.8 (− 3.1 to 1.6)

< 0.001

< 0.001

0.74